کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
3980036 1257399 2013 6 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Finding the right dose of fulvestrant in breast cancer
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی تومور شناسی
پیش نمایش صفحه اول مقاله
Finding the right dose of fulvestrant in breast cancer
چکیده انگلیسی

Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Cancer Treatment Reviews - Volume 39, Issue 2, April 2013, Pages 136–141
نویسندگان
, , , , , , ,